多西他赛联合奈达铂治疗晚期食管癌的临床观察

目的 观察多西他赛联合奈达铂治疗中晚期食管癌的有效性及安全性。方法全组共45例，其中男性30例，女性15例；年龄37岁-72岁，中位年龄54岁；鳞癌37例，腺癌8例；初治10例，复治35例，人组后给予多西他赛37．5mg／m^2，d1、d8；奈达铂80mg／m^2，d2。每3周重复。2周期后按WHO标准评价近期疗效和毒性反应。结果全组共接受了177周期治疗，每例1—6周期，平均3．9周期，均可评价疗效及毒副作用。全组1例CR（2．2％），16例PR（35．6％）。初治或复治、分期、病理类型对近期疗效均无影响。常见毒性反应为骨髓抑制。结论多它赛联合奈达铂治疗中晚期食道癌有较好的疗效，并且毒性反应可以控制，值得临床推广使用。

Evaluation of combined docetaxel and nedaplatin chemotherapy for advanced esophageal cancer

Objective The aim of this study was to evaluate the efficacy and safety of combination therapy with docetaxel and nedaplatin in advanced esophageal cancer. Methods 45 patients were included in the study （ 30 male, 15 female） ; median age ：54 years （ range 37 - 72） ; 37 cases of squamous cell carcinoma, 8 cases of adenoearcinoma. 10 patients never received treatment,35 retreatment patients who received more than one chemotherapy. Patients received docetaxel 37.5 mg/ m^2 on day 1,8, nedaplatin 80 mg/ m^2 on day 2, every 3 weeks. Evaluate the efficacy and toxicity every 2 cycles according to WHO criteria. Results A total of 177 chemotherapy cycles was administered. The median number of cycles was 3.9 （ range 1 - 6 ）. The response rate was 37.8% including one complete response,22 partial response. Initial treatment or retreatment, stage, histological type had no effect on short - term effect. Common toxicity was neutropenia. Conclusion the combination chemotherapy of docetaxel and nedaplatin is an active regimen with moderate toxicity in the treatment of patients with progression esophageal cancer.